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Development and evaluation of orally disintegrating tablets 
containing the mosapride resin complex
The purpose of this study was to prepare a mosapride 
citrate-resin (Amberlite® IRP 88) complex and orally fast-
disintegrating tablets of the resin complex. The resinate 
complex of mosapride-Amberlite® IRP 88, mass ratio 2:1, 
was prepared in an ethanol-water solution. The effects of 
alcohol concentration, temperature, and pH of the solution 
on complex formation were evaluated. The complex physi-
cochemical properties were characterized by differential 
scanning calorimetry, X-ray diffraction and scanning elec-
tron microscopy. Orally disintegrating tablets were prepared 
by direct compression and were optimized using the response 
surface method. Optimized orally fast-disintegrating tablets 
disintegrated within 18 s. The pH dependence of mosapride 
release from the tablet decreased drug dissolution in simu-
lated saliva, whereas it promptly released in the pH 1.0 
solution. The data reported herein clearly demon strate that 
tablets containing the mosapride-Amberlite® IRP 88 com-
plex for oral disintegration could be particularly useful for 
patients with swallowing difficulties.
Keywords: mosapride citrate, Amberlite® IRP 88 resin, resin 
complex, orally disintegrating tablet, physicochemical 
characterization, dissolution 
Mosapride citrate (MC) is a gastroprokinetic agent, which acts as a selective 5HT4 
agonist accelerating gastric emptying and is used for the treatment of acid reflux, irritable 
bowel syndrome and functional dyspepsia (1). The dose of MC is either 5 or 10 mg given 
three times a day. MC is a weakly basic drug available on the market as sustained release 
tablets, oral disintegrating tablets and chewable tablets (2). MC has low oral bioavailability 
of 8 % and a bitter taste (3). It is recommendable to mask the bitter taste of MC in order to 
achieve patient compatibility.
There are numerous effective taste masking technologies, such as common granula-
tion, coating processes and microencapsulation. Application of these approaches depends 
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taste of an ionic drug, the formation of a drug-resinate complex is the simplest method. 
Drug molecules interact with ion exchange resins and hence decrease its exposure to the 
taste buds while maintaining the concentration of the drug in saliva below the taste 
threshold value. It is expected that the drugs that bind to resins will be released in the GI 
tract through ion exchange with H+, Na+, or K+ in gastric and intestinal fluids (6).
Resins have been primarily used to mask taste and control liquid drug delivery systems 
(7–10). Many studies addressed the use of ion exchange resins for taste masking (11–13). 
However, few investigations have been reported on poorly water-soluble drugs. In order 
to improve the solubility of MC, an ethanol-water solution was used as the ion exchange 
reaction medium to form the mosapride-Amberlite® IRP complex. Amberlite® IRP is a 
weak acidic potassium cation exchange resin. It is widely used as a disintegrating and taste 
masking agent in oral dosage formulations (14).
Orally disintegrating tablets (ODT) provide pediatric, geriatric and bedridden pa-
tients with an easy method for taking medication. These tablets disperse in the oral cavity, 
and then the active ingredient dissolves in saliva to be absorbed. For some drugs, disinte-
grating tablets may have higher bioavailability than the conventional formulation (15, 16).
The aim of this work was to design a mosapride-Amberlite® IRP 88 complex and pre-
pare orally fast-disintegrating tablets to improve taste and palatability. The prepared and 
optimized drug-resinate complex with maximum drug loading was subjected to physico-
chemical characterization by differential scanning calorimetry (DSC), X-ray diffractometry 
(XRD), and scanning electron microscopy (SEM). Orally disintegrating tablets were com-
pressed by the direct method and optimized by a response surface method. The hardness, 
disintegration time and dissolution properties of the tablets were evaluated.
EXPERIMENTAL
Materials
Mosapride citrate was a gift from Lunan Pharmaceutical Group Corporation (Linyi, 
China). Polacrilin potassium NF (Amberlite® IRP 88) was kindly supplied by Rohm and 
Haas Company (Shanghai, China). Microcrystalline CEOLUS® PH-301 was supplied by 
AsahiKASEI (Japan). Low-Substituted Hypromellose-21 (LH-21) was supplied by Shin-Etsu 
(Japan). Pearlitol as mannitol was supplied by Roquette (France). All reagents and solvents 
were of analytical grade. 
Preparation and optimization of drug-resin complexes
Mosapride-resin complex (MR) was prepared by a simple aqueous binding process. 
The ion-exchange resin particles were dispersed in a drug ethanol solution with a mass 
ratio of 1:2 under magnetic stirring until equilibrium state. The influences of ethanol con-
centrations (40, 50, 60 and 75 %), pH 2.0, 3.0 and 4.2 of the solution, temperature (15, 20, 25 
and 30 °C) on drug loading were investigated. The complexes were separated by filtration 
and washed with deionized water to remove unbound drug and other ions. The com-
plexes were then dried in hot air oven for 4 h at 40 °C to constant mass and stored in a tight 
glass vial. Unbound drug was estimated by UV spectrophotometry at 272 nm and drug 
loading efficiency was calculated. To determine the equilibrium rate, 1 mL of supernatant 
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was collected and diluted with water at predetermined time intervals to monitor the 
changes of the MC content concentration in the solution by UV at a wavelength of 272 nm. 
The drug loading capacity (m/m) (Q) and adsorption ratio (E) at loading equilibrium were 




















= ×  (2)
where C0 (mg mL–1) is the initial MC concentration in solution and Ct is the concentration 
of MC at time t, V (mL) is the initial sample solution volume, WR (g) is the mass of dry 
resin.
Drug-polymer interaction studies
The thermal behavior of MC, resin, physical mixture of MC and resin (2:1), and MR 
was determined with the aid of a DSC Analyzer (Shimadzu, TA-60WS, Japan). The tempe-
rature was increased to 250 °C at the rate of 15 °C min–1.
The XRD patterns of MC, resin, MR, and physical mixture of MC and resin (2:1) were 
analyzed with an X-ray diffractometer (D/MAX-3C, Riguku Co., Japan) at a 56 kV voltage 
and 35 mA current. Samples were finely ground and irradiated with monochromatized 
Cu-Ka radiation after passing through Nickel filters and analyzed between 2 and 40° (2θ).
Morphologies of MC, resin, MR, and physical mixture of MC and resin were investi-
gated by SEM. Dried samples were attached to specimen stubs with a double-sided copper 
tape and sputter coated with gold-palladium in the presence of argon gas using a Hummer 
sputter coater (Anatech Ltd., Denver, NC). The samples were recorded with a JEOL JSM-840 
scanning electron microscope (JEOL USA Inc., Peabody, MA) at a 5 kV accelerating voltage 
and a probe current of 3 × 10−11 A.
Preparation and experimental design of tablets
LH-21, CEOLUS® PH-301, Pearlitol® 300DC were chosen as fillers and sodium stearyl 
fumarate (PRUV®) was used as lubricant to prepare the orally disintegrating tablets. The 
percent of LH-21 in the formulation was determined by the single factor experiment. Micro-
crystalline cellulose (MCC) is a binder, owing to its excellent compatibility, and is also 
known to be self-disintegrating in the direct compression process. Mannitol (Man) was 
used as a diluent because of its sweet taste and cooling sensation. To optimize the formu-
lation, MCC/Man ratio and tablet porosity were chosen as controlling factors, and oral 
disintegration time was set as the response variable. As shown in Table 1, five formulations 
with different MCC/Man ratios were compressed with a diameter of 8 mm using a single 
punch tablet machine and compression pressure at 20~30 N with about 200 mg mass. The 
different kinds of tablets with various porosity and oral disintegration times were ob-
tained. Based on these data, the response surface and contour plots of disintegration were 
obtained with Origin 8.0.
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Measurement of tablet hardness
The hardness/crushing strength (17) measured in kg cm–2 of six tablets were deter-
mined using a Hardness Tester (78X-2, Huanghai Instrument Co., Ltd., China). The tensile 
strength, T, for crushing (MPa) was measured using the following equation (3):
 2FT
DHπ
=  (3) 
where F is the crushing load (N), d is the diameter (m) and t is the thickness (m).
Measurement of tablet porosity
Tablet porosity was measured with an oil pressurized single punch tablet press under 















where d1 (mm) is the original tablet diameter, h1 (mm) is the original tablet thickness (mm), 
d2 (mm) is the tablet diameter and h2 (mm) is the tablet thickness (mm). Tablet diameter and 
thickness were determined using a micrometer caliper (Shenyang Measurement Factory, 
China).
Disintegration test 
Disintegration test was conducted according to the method described in the Pharma-
copoeia of the People’s Republic of China (2010). Six tablets were separately put into the test 
apparatus. The basket was put into 800 mL of water at 37 ± 0.2 °C. Time was recorded when 
the tablet was fully disintegrated.
Table I. Tablet formulations for optimization
Ingredients (mg/tablet) F1 F2 F3 F4 F5
Ceolus® PH-301 110 104 90 62 50
Pearlitol® 300DC 70 76 90 118 130
LH-21 20 20 20 20 20
PRUV® 1 1 1 1 1





















Dissolution test was performed using a dissolution apparatus type II (ZRS-8G, Tianjin 
University Instrument Factory, China) in triplicate in 250 mL dissolution media of various 
pH 1.0, 1.5, 2.5 (hydrochloric acid solution), pH 3.5, 4.5 (acetate buffer solution), pH 5.5, 6.5 
(phosphate buffer solution) and simulated saliva (NaCl 8.00 g, KH2PO4 0.19 g, Na2HPO4 
2.38 g, in 1 L distilled water; pH 6.8) (18) at 37 ± 0.5 °C at a rotation speed of 50 rpm according 
to the Pharmacopoeia of the People’s Republic of China. 2 mL of sample was replaced with 
dissolution medium at predetermined time and was filtered through a 0.45 µm film. The 
concentration was analyzed using a spectrophotometer at the wavelength of 272 nm.
RESULTS AND DISCUSSION
Effects of ethanol concentration, solution pH and temperature on drug loading
MC concentration was 0.8 mg mL–1 in a 100 % ethanol solution while the drug-resin 
ratio was 2:1. Mosapride could not be loaded on Amberlite® IRP 88 in anhydrous ethanol, 
but it could form a complex in aqueous alcoholic medium. Increasing the ethanol concentra-
tion could decrease the drug adsorption capacity (Q). The significant improvement of drug 
adsorption ratio in 40 % aqueous alcoholic medium (92.2 %) compared to that of 75 % aque-
ous alcoholic medium (8.4 %) is depicted in Fig. 2. The solubility of mosapride was increased 
in the alcoholic solution to form a complex and reduce the equilibrium time.
Fig. 3 shows the effects of temperature on the adsorption ratio and adsorption capacity. 
It was found that adsorption capacity was about 1.0~1.5 g g–1 at the temperature from 30 to 
15 °C. Due to the increment in adsorption ratio with decreased temperature, further expe ri-
ments were carried out at 25 °C.
The pH of the solution is a very important parameter in drug adsorption on resin. At 
pH 2.0, the drug adsorption capacity of 0.13 g g–1 was the lowest because Amberlite® IRP 88 
is available in unionized molecular form in an acidic aqueous solution. By increasing the pH 
from 2.0 to 4.0, an increase in drug loading is observed (pH 4.0, 2.0 g g–1) in Fig. 4. At pH 
Fig. 2. Effect of ethanol concentration on the drug adsorption capacity, Q at 25 °C. Data are expressed 
as the mean ± SD (n = 3).
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4.2, both the drug and the resin were ionized in a sufficient quantity and interacted to form 
the resin complex.
Differential scanning calorimetry
DSC curves of MC, resin, MR, and physical mixture are presented in Fig. 5. MC shows 
a melting endothermic peak at 119.04 °C (Fig. 5c). The DSC thermogram of resin shows a 
broad endotherm peak at 95.54 °C due to the dehydration of resin (Fig. 5d). The melting 
endothermic peak of the drug and a broad endothermic peak were observed in the ther-
mograms of the physical mixture (Fig. 5b). A sharp endothermic peak of mosapride in MR 
(Fig. 5a) was observed at 155.38 °C, probably due to the bonding force of mosapride while 
resin was so weak that it was discomposed by heating.
X-ray diffractometry studies
The powder XRD patterns of MC, Amberlite® IRP 88 resin, MR, and physical mixture 
are shown in Fig. 6. The XRD pattern of MC in Fig. 6 shows the strong intensity of the 
Fig. 3. Effects of temperature on: a) drug adsorption ratio (E), and b) the drug adsorption capacity (Q). 
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diffraction peaks. For the physical mixture in Fig. 6, drug molecules were outside the resin 
and crystalline sharp peaks appeared in the diffractogram. The XRD pattern of MR in Fig. 
6 indicated the disappearance of crystalline form in case of the drug resinate complex 
compared to the drug alone or its physical mixture. The resin Amberlite® IRP 88 X-ray 
diffractogram displays a diffused peak due to their amorphous state in Fig. 6.
Morphology
Scanning electron microscopy (SEM) images of MC, Amberlite® IRP 88 resin, MR, and 
MC resin physical mixture are presented in Fig. 7. It appears that the size of drug crystals 
ranged from 1–2 µm to even more than 100 µm (Fig. 7c). The Amberlite® IRP 88 resin is 
irregular in shape and appears as separate pieces (Fig. 7d). The SEM image of physical 
mixture (Fig. 7b) shows embedded particles of MC and Amberlite® IRP 88 with a morphology 
comparable to pure components, revealing no apparent interaction between both species 
Fig. 4. Effect of pH on drug loading capacity, Q. Data are expressed as the mean ± SD (n = 3).
Fig. 5. DSC thermograms of: a) MR, b) physical mixture, c) MC and d) Amberlite® IRP 88.
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in the solid state. After forming the resin-complex, the morphology MR (Fig. 7a) appeared 
different from the drug, the resin or their physical mixture. The features of drug crystals 
were not easily detectable, indicating formation of a different compound.
Formulation optimization
LH-21, CEOLUS® PH-301, Pearlitol® 300DC were chosen as excipients, sodium stearyl 
fumarate (PRUV®) was used as lubricant to prepare the orally disintegrating tablets and 
Fig. 6. X-Ray diffractograms of: a) MR, b) physical mixture, c) MC, d) Amberlite® IRP 88.
Fig. 7. Scanning electron micrographs of: a) MR, b) physical mixture, c) MC, d) Amberlite® IRP 88.
            a)                                                                   b)
            c)                                                                   d)
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the percent of LH-21 in the formulation was determined by the single factor experiment. 
To optimize the formulation, MCC/Man ratio and tablet porosity were selected as control-
ling factors, and oral disintegration times were set as response variables. The response 
surface and contour plots of disintegration were obtained with Origin 8.0 and are given in 
Fig. 8. The plot of the response surface and contour indicates that disintegration time de-
creased with an increase in porosity at the same MCC/Man ratio. This may be explained 
by the fact that tablets with high porosity can uptake water rapidly and the L-HPC can 
swell to break the solid bridge. For tablets with the same porosity, the disintegration time 
was the shortest with MCC/Man at the 0.75 ratio. Consequently, the combination of Man 
and MCC showed the desired flowability, compressibility and rapid disintegration.
The swelling of L-HPC had less effect on the disintegration of the tablet compared to 
tablets containing more insoluble MCC. There are about 2.0 % water-soluble substances in 
CEOLUS® PH-301, and a gel-like layer will be formed when water penetrates into tablets 
with an increased MCC/Man ratio. In a viscous gel layer, the diffusion rate of water should 
be reduced. As the mean diameter of CEOLUS® PH-301 and Pearlitol® 300DC is 50 µm and 
250 µm, respectively, the contact surface with higher MCC/Man ratio formations may be 
much larger than that of a low MCC/Man ratio. The bonding force was enhanced and the 
disintegration time was also decreased.
Hardness of a tablet is defined as the force applied across its diameter in order to 
break the tablet. Tablets should be able to resist chipping, abrasion or breaking under the 
conditions of storage, transformation or handling, but there should be no problems in 
their disintegration or dissolution. It is generally recognized that sufficient hardness 
would be 2 kP or higher. In addition, the desirable oral disintegration time would generally 
be 30 s or shorter in case of orally disintegrating tablets. The desirable disintegration time 
is 25 s, and the contour plots show that all the formulations with porosity above 0.225 can 
achieve this requirement. Mannitol is commonly used in the manufacture of chewable 
tablet formulations because of its negative heat of solution, sweetness and better mouth 
feel. The MCC/Man ratio was 0.75 and tablets were prepared at 3 kP with a disintegration 
time of 18 s.
Fig. 8. Response surface and contour plots of disintegration time. MCC/Man ratio is ratio of micro-
crystalline cellulose and mannitol.
a)                                                                              b)
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Drug release from the drug resin complex depends on the environment pH and ionic 
strength within the gastrointestinal tract, as well as on the properties of the resin (19). The 
pH, ionic species and strength effects on drug dissolution from MR-ODT were studied. In 
order to confirm the taste masking results, drug release in simulated saliva (pH 6.8) was 
also studied.
The dissolution profile (Fig. 9) of mosapride from the MR-ODT in various pH aqueous 
solutions indicated that mosapride was released rapidly and completely in solutions of pH 
< 2.5. More than 75 % of bound mosapride was released in 10 min at pH 3.5, but less than 
10 % of bound mosapride was released in 30 min in solutions of pH > 5.5. All the results 
demonstrated that drug release from the tablets was strongly pH dependent. The pH de-
pendence of mosapride release from the complex could decrease drug dissolution in the 
Fig. 9. Effect of solution pH on the dissolution of mosapride from mosapride-resin complex orally 
disintegrating tablets (MR-ODT). Data are expressed as the mean ± SD (n = 3).
Fig. 10. Dissolution profiles of mosapride citrate orally disintegrating tablets (MC-ODT) and mo-
sapride-resin complex orally disintegrating tablets (MR-ODT) in simulated saliva. Data are expressed 
as the mean ± SD (n = 3).
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oral cavity, whereas it immediately releases in the stomach (20). At pH 6.8 (salivary pH), 
drug release was delayed and was effective for taste masking. Amberlite® IRP 88 is a weak 
acidic, potassium form cation-exchange resin (21). The high affinity of Amberlite® IRP 88 
to hydrogen ions can lead to fast desorption of bound ions when they are exposed to an 
acidic environment such as the stomach (22).
The dissolution profile of MR-ODT in simulated saliva is represented in Fig. 10 and 
MC-ODT was used as a reference tablet. In four minutes, the drug released from MR-ODT 
and the MC-ODT content in simulated saliva was about 0.5 and 15 %, respectively. The 
delayed dissolution observed with the resin complex can be attributed to the resin-com-
plex formulation. This result suggested that there should be less drug release in the oral 
cavity when taking optimized MR-ODT than MC-ODT. The bitter taste masking effect will 
be investigated in future studies.
CONCLUSIONS
In this study, a resin complex and orally disintegrating tablets were successfully pro-
duced using mannitol, L-HPC and MCC as excipients. Differential scanning calorimetry, 
X-ray diffraction and scanning electron microscopy demonstrated the complex formation 
and indicated that the drug was dispersed evenly into the resin to form the resin complex 
and showed some disappearance of crystallinity. The oral disintegrating tablet disinte-
grated within 18 s. This oral disintegrating tablet can be used as a potential drug delivery 
system of mosapride citrate, especially for the pediatric and geriatric patients and those 
with swallowing difficulties.
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